Soliqua is a once-daily injection that combines Lantus, or insulin glargine, with lixisenatide. The treatment is intended for adults with type 2 diabetes who cannot control their glycemic levels with basal insulin.
Paris, France-based Sanofi expects Soliqua to hit pharmacy shelves in January 2017.
More articles on supply chain:
6 latest FDA approvals
Bundled payments reach a turning point: Four strategies for success
Gartner names top 25 supply chains in healthcare
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.